76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
SCYNEXIS Inc
Closed
0.89 4.71
Overview
Share price change
24h
Min
0.85
Max
0.89
Income | -958K -5.4M |
|---|---|
Sales | -720K 257K |
EPS | -0.11 |
Profit margin | -2,097.665 |
Employees | 28 |
EBITDA | -4.9M -8.6M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +378.72% upside |
Market Cap | -3.1M 35M |
|---|---|
Previous open | -3.82 |
Previous close | 0.89 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
SCYNEXIS Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
SCYNEXIS Inc Forecast
Price Target
By TipRanks
378.72% upside
12 Months Forecast
Average 4.5 USD 378.72%
High 5 USD
Low 4 USD
Based on 2 Wall Street analysts offering 12 month price targets forSCYNEXIS Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
